Alivus Life Sciences · NSE: ALIVUS · BSE: 543322
Q1 FY26 results · Apr–Jun 2025
Alivus Life Sciences reported revenue from operations of ₹601.85 crore (up 2.2% from Q1 FY25) and net profit of ₹121.53 crore (up 9.0% from Q1 FY25) for Q1 FY26 (Apr–Jun 2025), on a standalone basis.
| Item | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 601.85 | 588.62 | +2.2% | 649.54 | −7.3% |
| Other income | 8.98 | 5.49 | +63.6% | 10.09 | −10.9% |
| Total income | 610.83 | 594.11 | +2.8% | 659.63 | −7.4% |
| Profit before tax | 162.98 | 150.24 | +8.5% | 191.29 | −14.8% |
| Net profit for the period | 121.53 | 111.48 | +9.0% | 141.87 | −14.3% |
| EPS, basic (₹) | 9.91 | 9.10 | +8.9% | 11.57 | −14.3% |
| Net margin (%) | 20.2 | 18.9 | 21.8 |
Standalone
- Filed with BSE
- 01 Aug 2025, 19:07 IST
- Board meeting
- 01 Aug 2025
- Period
- 01 Apr 2025 to 30 Jun 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE